[PMC free content] [PubMed] [CrossRef] [Google Scholar] 44. was assessed by MTT assays. In addition, the activation status of the pathway as well as induction of autophagy were analyzed by Western blotting. Quiescent healthy T lymphocytes were unaffected by the drugs whereas mitogen-stimulated lymphocytes as well as leukemic cell lines displayed a cell cycle block, caspase-dependent apoptosis, and dephosphorylation of key components of the signaling pathway. Autophagy was also induced in proliferating lymphocytes and in JURKAT and MOLT-4 cell lines. When autophagy was inhibited by 3-methyladenine or Bafilomycin A1, drug cytotoxicity was increased, indicating that autophagy is usually a protective mechanism. Therefore, our findings suggest that PI3K/Akt/mTOR Rabbit Polyclonal to EFNB3 inhibitors preserve lymphocyte viability. This is a valuable result to be taken into account when selecting drugs for targeted cancer therapy in order to minimize detrimental effects on immune function. and than p110 or pan PI3K class I inhibitors . Natural killer cell-mediated cytotoxicity as well as antibody dependent cellular cytotoxicity against tumor cells were significantly impaired by pan class I PI3K inhibitors, whereas p110 selective drugs had no effect [51, 57]. Other authors have shown recently that single inhibitors of class I PI3K isoforms in T-lymphocytes exerted a less potent impairment of T-cell activation than simultaneous inhibition of two or more isoforms . These results suggest that complete blockade of class I PI3K activity strongly impairs T lymphocyte proliferation and activation and and in vivo. Clin Cancer Res. 2011;17:7116C7126. [PubMed] [Google Scholar] 31. Baumann P, Schneider L, Mandl-Weber S, Oduncu F, Schmidmaier R. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is usually highly effective in multiple myeloma. Anti-cancer drugs. 2012;23:131C138. [PubMed] [Google Scholar] 32. Simioni C, Cani A, Martelli AM, Zauli G, Alameen AA, Ultimo S, Tabellini G, McCubrey JA, Capitani S, Neri LM. The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells. Oncotarget. 2015;6:17147C17160. doi:?10.18632/oncotarget.3940. [PMC free article] [PubMed] [CrossRef] [Google Scholar] 33. Simioni C, Neri LM, Tabellini G, Ricci F, Bressanin D, Chiarini F, Evangelisti C, Cani A, Tazzari PL, Melchionda F, Pagliaro P, Pession A, McCubrey Betamethasone acibutate JA, et al. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia. 2012;26:2336C2342. [PubMed] [Google Scholar] 34. Simioni C, Martelli AM, Cani A, Cetin-Atalay R, McCubrey JA, Capitani S, Neri LM. The Akt inhibitor MK-2206 is usually cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated Akt-1 and synergizes with conventional chemotherapy. Oncotarget. 2013;4:1496C1506. doi:?10.18632/oncotarget.1236. [PMC free article] [PubMed] [CrossRef] [Google Scholar] 35. Cani A, Simioni C, Martelli AM, Zauli G, Tabellini G, Ultimo S, McCubrey JA, Capitani S, Neri LM. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia. Oncotarget. 2015;6:6597C6610. doi:?10.18632/oncotarget.3260. [PMC free article] [PubMed] [CrossRef] [Google Scholar] 36. Wang Y, Liu J, Qiu Y, Jin M, Chen X, Fan G, Wang R, Kong D. ZSTK474, a specific class I phosphatidylinositol 3-kinase inhibitor, induces G1 arrest and autophagy in human breast cancer MCF-7 cells. Oncotarget. 2016 doi:?10.18632/oncotarget.7658. [PMC free article] [PubMed] [CrossRef] [Google Scholar] 37. Tasian SK, Teachey DT, Rheingold SR. Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies. Frontiers in oncology. 2014;4:108. [PMC free article] [PubMed] [Google Scholar] 38. Janes MR, Vu C, Mallya S, Shieh MP, Limon JJ, Li LS, Jessen KA, Martin MB, Ren P, Lilly MB, Sender LS, Liu Y, Rommel C, et al. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia. 2013;27:586C594. [PMC free article] [PubMed] [Google Scholar] 39. Rubinsztein Betamethasone acibutate DC, Codogno P, Levine B. Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov. 2012;11:709C730. [PMC free article] [PubMed] [Google Scholar] 40. Gewirtz DA. The autophagic response to radiation: relevance for radiation sensitization in cancer therapy. Radiation research. 2014;182:363C367. [PubMed] [Google Scholar] 41. Klionsky DJ. Stepping back from the guidelines: Where do we stand? Autophagy. 2016;12:223C224. [PMC free article] [PubMed] [Google Scholar] 42. Kampa-Schittenhelm KM, Heinrich MC, Akmut Betamethasone acibutate F, Rasp KH, Illing B, Dohner H, Dohner K, Schittenhelm MM. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia. Mol Cancer. 2013;12:46. [PMC free article] [PubMed] [Google Scholar] 43. Simioni C, Betamethasone acibutate Cani A, Martelli AM, Zauli G, Tabellini G, McCubrey J, Capitani S, Neri LM. Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. Oncotarget. 2014;5:10034C10047. doi:?10.18632/oncotarget.2490. [PMC free article] [PubMed] [CrossRef] [Google Scholar] 44. Mu Q, Ma Q, Lu S, Zhang T, Yu M, Huang X, Chen J, Jin J. 10058-F4, a c-Myc.